A clinical trial involving somatropin recombinant, listed as NCT05353192, was recorded as completed on August 6, 2026. The study, titled "A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia," is registered as a Phase 4 trial.
According to the trial record, the study's status has been updated to COMPLETED. The listing does not include reported results or outcome data as part of this update. No efficacy or safety findings are stated in the available event information.
Somatropin recombinant carries an unapproved research status in the context described here. The trial record identifies the study population as children with achondroplasia, and the phase designation is Phase 4.
This update reflects only the change in trial status and the associated date as recorded in the clinical trial registry. No additional details about trial design, enrollment figures, or results have been provided alongside this status change. Readers interested in the broader context of this compound can consult the compound overview for further information.